

Martin Schlumberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8425677/publications.pdf>

Version: 2024-02-01

155
papers

31,583
citations

13332

70
h-index

8878

150
g-index

159
all docs

159
docs citations

159
times ranked

16193
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives. <i>Endocrine</i> , 2022, 75, 330-337.	1.1	10
2	Discussion À propos de la communicationÂ: Â«Âcancer de la thyroÃ-deÂ: le surdiagnostic doit aussi Âtre ÂvitÂ© chez lâ€™enfant et lâ€™adolescentÂ». <i>Bulletin De L'Academie Nationale De Medecine</i> , 2022, 206, 347-347.	0.0	0
3	Functional imaging in thyroid cancer patients with metastases and therapeutic implications. <i>Presse Medicale</i> , 2022, 51, 104113.	0.8	9
4	Global thyroid estimates in 2020. <i>Lancet Diabetes and Endocrinology,the</i> , 2022, 10, 235-236.	5.5	5
5	Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 669-679.	1.9	1
6	Post-operative radioactive iodine administration in patients with low-risk thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2022, 18, 585-586.	4.3	1
7	Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer. <i>Endocrine</i> , 2021, 71, 434-442.	1.1	19
8	Consequences of atmospheric contamination by radioiodine: the Chernobyl and Fukushima accidents. <i>Endocrine</i> , 2021, 71, 298-309.	1.1	11
9	Current practice in patients with differentiated thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2021, 17, 176-188.	4.3	161
10	Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. <i>Endocrine-Related Cancer</i> , 2021, 28, 15-26.	1.6	12
11	Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1927-1933.	1.8	22
12	RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3238-3249.	3.3	11
13	The importance of the RET gene in thyroid cancer and therapeutic implications. <i>Nature Reviews Endocrinology</i> , 2021, 17, 296-306.	4.3	76
14	Thyroid cancer incidence in children and adolescents. <i>Lancet Diabetes and Endocrinology,the</i> , 2021, 9, 128-129.	5.5	11
15	Differentiated Thyroid Cancer in Children and Adolescents: Long Term Outcome and Risk Factors for Persistent Disease. <i>Cancers</i> , 2021, 13, 3732.	1.7	16
16	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2359-2366.	0.8	64
17	Advances in Functional Imaging of Differentiated Thyroid Cancer. <i>Cancers</i> , 2021, 13, 4748.	1.7	11
18	Redifferentiation-facilitated radioiodine therapy in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, T179-T191.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Postoperative Management of Differentiated Thyroid Cancer. , 2021, , 440-446.e2.		0
20	Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report. <i>Current Oncology</i> , 2021, 28, 5401-5407.	0.9	5
21	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 312-317.	1.9	8
22	Surgery in the context of kinase inhibitor therapy for locally invasive thyroid cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 650-655.	0.5	9
23	Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. <i>Head and Neck</i> . 2020. 42. 3446-3459.	0.9	24
24	Comparison of simultaneous 18F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3066-3073.	3.3	27
25	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2773-2781.	0.8	33
26	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. <i>Thyroid</i> , 2019, 29, 1820-1827.	2.4	15
27	F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients. <i>Thyroid</i> , 2019, 29, 1457-1464.	2.4	24
28	Thyroid Cancer Patients With No Evidence of Disease: The Need for Repeat Neck Ultrasound. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4981-4989.	1.8	50
29	Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma. <i>European Journal of Radiology</i> , 2019, 119, 108650.	1.2	12
30	Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy. <i>Oncolmmunology</i> , 2019, 8, e1574197.	2.1	16
31	Redifferentiation of a <i>BRAF</i> ^{K601E} -Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment. <i>Thyroid</i> , 2019, 29, 735-742.	2.4	35
32	Exposureâ€Response Modeling and Simulation of Progressionâ€Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer. <i>Clinical and Translational Science</i> , 2019, 12, 459-469.	1.5	6
33	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	1.8	103
34	Occult Contralateral Lateral Lymph Node Metastases in Unilateral N1b Papillary Thyroid Carcinoma. <i>World Journal of Surgery</i> , 2019, 43, 818-823.	0.8	15
35	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 213-220.	5.5	86
36	Genetic susceptibility to radiation-related differentiated thyroid cancers: a systematic review of literature. <i>Endocrine-Related Cancer</i> , 2019, 26, R583-R596.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1772-1780.	3.3	62
38	Treatment of refractory thyroid cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R209-R223.	1.6	63
39	Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect. <i>European Journal of Cancer</i> , 2018, 97, 57-58.	1.3	26
40	Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. <i>Thyroid</i> , 2018, 28, 72-78.	2.4	89
41	Transcriptional landscape of a RET C634Y -mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers. <i>Stem Cell Research</i> , 2018, 26, 8-16.	0.3	15
42	Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 618-626.	5.5	115
43	Follow-up of differentiated thyroid cancer – what should (and what should not) be done. <i>Nature Reviews Endocrinology</i> , 2018, 14, 538-551.	4.3	85
44	Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. <i>Human Reproduction</i> , 2018, 33, 1408-1416.	0.4	14
45	A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6021-6021.	0.8	7
46	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>European Journal of Cancer</i> , 2017, 75, 213-221.	1.3	59
47	Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. <i>Endocrine</i> , 2017, 56, 121-128.	1.1	82
48	Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1020-1031.	1.8	41
49	Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 335-347.	2.2	38
50	Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Annals of Oncology</i> , 2017, 28, 2813-2819.	0.6	166
51	Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with the highest risk RET mutation. <i>Stem Cell Research</i> , 2017, 23, 154-157.	0.3	1
52	The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 638-646.	3.3	16
53	Comparison of Empiric Versus Whole-Body/Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 717-722.	2.8	81
54	NADPH Oxidase NOX4 Is a Critical Mediator of BRAF ^{V600E} -Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 864-877.	2.5	63

#	ARTICLE	IF	CITATIONS
55	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
56	Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1006-1010.	3.3	13
57	Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2733-2741.	1.8	38
58	Anatomic Variability of the Upper Mediastinal Lymph Node Level VII. World Journal of Surgery, 2016, 40, 1899-1903.	0.8	1
59	Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. Lancet Diabetes and Endocrinology, 2016, 4, 933-942.	5.5	200
60	Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/L1 therapy. European Journal of Cancer, 2016, 65, 33-42.	1.3	58
61	Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4103-4109.	1.8	78
62	Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with RET mutation. Stem Cell Research, 2016, 17, 154-157.	0.3	13
63	Management of advanced medullary thyroid cancer. Lancet Diabetes and Endocrinology, 2016, 4, 64-71.	5.5	100
64	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26, 1-133.	2.4	10,674
65	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clinical Cancer Research, 2016, 22, 44-53.	3.2	193
66	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer, 2015, 121, 2749-2756.	2.0	159
67	Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Science, 2015, 106, 1714-1721.	1.7	111
68	Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort. Thyroid, 2015, 25, 386-391.	2.4	52
69	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal of Medicine, 2015, 372, 621-630.	13.9	1,526
70	Postoperative Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: An Important Imaging Modality in Patients with Aggressive Histology of Differentiated Thyroid Cancer. Thyroid, 2015, 25, 437-444.	2.4	45
71	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610.	2.4	1,738
72	18F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. Oral Oncology, 2015, 51, 370-375.	0.8	9

#	ARTICLE	IF	CITATIONS
73	18Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1941-1942.	3.3	32
74	Thyroid Radiation Dose and Other Risk Factors of Thyroid Carcinoma Following Childhood Cancer. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4282-4290.	1.8	33
75	Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. Journal of Clinical Oncology, 2015, 33, 2885-2892.	0.8	63
76	Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).. Journal of Clinical Oncology, 2015, 33, 6014-6014.	0.8	2
77	Effect of age and lenvatinib treatment on overall survival for patients with ¹³¹ I-refractory differentiated thyroid cancer in SELECT.. Journal of Clinical Oncology, 2015, 33, 6048-6048.	0.8	8
78	Treatment of distant metastases from follicular cell-derived thyroid cancer. F1000prime Reports, 2015, 7, 22.	5.9	12
79	Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes and Endocrinology, 2014, 2, 356-358.	5.5	283
80	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with ¹³¹ I-refractory differentiated thyroid cancer (SELECT).. Journal of Clinical Oncology, 2014, 32, LBA6008-LBA6008.	0.8	23
81	Comments on "Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial". Chinese Clinical Oncology, 2014, 3, 8.	0.4	7
82	Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma. World Journal of Surgery, 2013, 37, 1951-1958.	0.8	97
83	Comparison of Transcriptomic Signature of Post-Chernobyl and Postradiotherapy Thyroid Tumors. Thyroid, 2013, 23, 1390-1400.	2.4	6
84	Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. European Journal of Endocrinology, 2013, 169, 689-693.	1.9	56
85	Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?. Annals of Oncology, 2013, 24, 2201-2204.	0.6	6
86	Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study.. Journal of Clinical Oncology, 2013, 31, 6000-6000.	0.8	19
87	A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor Vandetanib. Archives of Dermatology, 2012, 148, 1418.	1.7	49
88	2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer. European Thyroid Journal, 2012, 1, 5-14.	1.2	137
89	Optimization of Staging of the Neck With Prophylactic Central and Lateral Neck Dissection for Papillary Thyroid Carcinoma. Annals of Surgery, 2012, 255, 777-783.	2.1	149
90	ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer. European Journal of Endocrinology, 2012, 166, 5-11.	1.9	104

#	ARTICLE	IF	CITATIONS
91	Somatic <i>RAS</i> Mutations Occur in a Large Proportion of Sporadic <i>RET</i> -Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2031-E2035.	1.8	131
92	Postradioiodine Treatment Whole-Body Scan in the Era of 18-Fluorodeoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with Elevated Serum Thyroglobulin Levels. <i>Thyroid</i> , 2012, 22, 832-838.	2.4	71
93	Discriminating Gene Expression Signature of Radiation-Induced Thyroid Tumors after Either External Exposure or Internal Contamination. <i>Genes</i> , 2012, 3, 19-34.	1.0	8
94	Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1663-1673.	13.9	570
95	Kinase inhibitors for advanced medullary thyroid carcinoma. <i>Clinics</i> , 2012, 67, 125-129.	0.6	16
96	Effects of vandetanib on body composition in patients with advanced medullary thyroid carcinomas: Results from a placebo-controlled study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5569-5569.	0.8	0
97	Target therapies for radioiodine refractory advanced thyroid tumors. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 40-4.	1.8	5
98	Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2796-2804.	1.8	187
99	Treatment and follow-up of low-risk patients with thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2011, 7, 625-628.	4.3	22
100	Strategy to Find Molecular Signatures in a Small Series of Rare Cancers: Validation for Radiation-Induced Breast and Thyroid Tumors. <i>PLoS ONE</i> , 2011, 6, e23581.	1.1	15
101	Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2741-2749.	1.8	54
102	Long-Term Follow-Up of Patients with Papillary and Follicular Thyroid Cancer: A Prospective Study on 715 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1352-1359.	1.8	199
103	Gene expression signature discriminates sporadic from post-radiotherapy-induced thyroid tumors. <i>Endocrine-Related Cancer</i> , 2011, 18, 193-206.	1.6	39
104	Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. <i>Endocrine-Related Cancer</i> , 2011, 18, 159-169.	1.6	138
105	¹⁸ F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2277-2285.	3.3	86
106	Role of H ₂ O ₂ in <i>RET/PTC1</i> Chromosomal Rearrangement Produced by Ionizing Radiation in Human Thyroid Cells. <i>Cancer Research</i> , 2010, 70, 4123-4132.	0.4	78
107	Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 767-772.	0.8	484
108	Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances. <i>Thyroid</i> , 2009, 19, 1393-1400.	2.4	80

#	ARTICLE	IF	CITATIONS
109	Charcoal Suspension Tattoo Localization for Differentiated Thyroid Cancer Recurrence. <i>Annals of Surgical Oncology</i> , 2009, 16, 2602-2608.	0.7	40
110	Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. <i>Thyroid</i> , 2009, 19, 565-612.	2.4	1,247
111	Therapeutic Administration of ¹³¹ I for Differentiated Thyroid Cancer: Radiation Dose to Ovaries and Outcome of Pregnancies. <i>Journal of Nuclear Medicine</i> , 2008, 49, 845-852.	2.8	120
112	Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. <i>European Journal of Endocrinology</i> , 2008, 158, 239-246.	1.9	243
113	New therapeutic approaches to treat medullary thyroid carcinoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 22-32.	2.9	161
114	Ultrasound Criteria of Malignancy for Cervical Lymph Nodes in Patients Followed Up for Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3590-3594.	1.8	455
115	Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4185-4190.	1.8	246
116	How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 641-650.	2.9	24
117	Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2487-2495.	1.8	180
118	Distributing KI pills to minimize thyroid radiation exposure in case of a nuclear accident in France. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 611-611.	2.9	12
119	The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 112-121.	2.9	90
120	Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 260-269.	2.9	112
121	Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 926-932.	1.8	405
122	Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2892-2899.	1.8	1,334
123	Chemoembolization for Liver Metastases from Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2496-2499.	1.8	110
124	Dosimetry of Beta-Emitting Radionuclides at the Tissular Level Using Monte Carlo Methods. <i>Nuclear Science and Engineering</i> , 2005, 149, 124-130.	0.5	0
125	Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5723-5729.	1.8	504
126	Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. <i>European Journal of Endocrinology</i> , 2005, 153, 651-659.	1.9	174

#	ARTICLE	IF	CITATIONS
127	Follicular Thyroid Tumors with the PAX8-PPAR β 1 Rearrangement Display Characteristic Genetic Alterations. <i>American Journal of Pathology</i> , 2005, 167, 223-231.	1.9	79
128	Current Concepts in the Management of Unilateral Recurrent Laryngeal Nerve Paralysis after Thyroid Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3084-3088.	1.8	107
129	Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. <i>European Journal of Endocrinology</i> , 2004, 150, 105-112.	1.9	295
130	Medullary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2004, 61, 299-310.	1.2	291
131	Second primary malignancies in thyroid cancer patients. <i>British Journal of Cancer</i> , 2003, 89, 1638-1644.	2.9	557
132	Rationale for Central and Bilateral Lymph Node Dissection in Sporadic and Hereditary Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2070-2075.	1.8	326
133	Positive Predictive Value of Serum Thyroglobulin Levels, Measured during the First Year of Follow-Up after Thyroid Hormone Withdrawal, in Thyroid Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1107-1111.	1.8	247
134	Expression of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase (ThoX, LNOX, Duox) Genes and Proteins in Human Thyroid Tissues1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3351-3358.	1.8	96
135	Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase Flavoprotein DUOX Genes and Proteins in Human Papillary and Follicular Thyroid Carcinomas. <i>Thyroid</i> , 2001, 11, 1017-1023.	2.4	48
136	Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. <i>British Journal of Cancer</i> , 2000, 83, 715-718.	2.9	119
137	Clinical use of recombinant human TSH in thyroid cancer patients. <i>European Journal of Endocrinology</i> , 2000, 143, 557-563.	1.9	54
138	Is Diagnostic Iodine-131 Scanning Useful after Total Thyroid Ablation for Differentiated Thyroid Cancer?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 175-178.	1.8	317
139	Expression of Pendrin and the Pendred Syndrome (PDS) Gene in Human Thyroid Tissues*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2028-2033.	1.8	103
140	A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3877-3885.	1.8	447
141	Thyroid carcinoma. <i>Cancer</i> , 1998, 83, 403-404.	2.0	3
142	Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. <i>Clinical Endocrinology</i> , 1998, 48, 265-273.	1.2	468
143	Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2675-2680.	1.8	127
144	Post-Chernobyl Thyroid Carcinoma in Belarus Children and Adolescents: Comparison with Naturally Occurring Thyroid Carcinoma in Italy and France1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3563-3569.	1.8	167

#	ARTICLE	IF	CITATIONS
145	131I Therapy for Elevated Thyroglobulin Levels. <i>Thyroid</i> , 1997, 7, 273-276.	2.4	196
146	Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. <i>Journal of Nuclear Medicine</i> , 1996, 37, 606-12.	2.8	124
147	Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. <i>British Journal of Cancer</i> , 1995, 71, 363-365.	2.9	140
148	Outcome of pregnancy in women with thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 150-151.	1.8	29
149	Immunohistochemical study of adrenocortical carcinoma. Predictive value of the D11 monoclonal antibody. <i>Cancer</i> , 1993, 72, 3296-3303.	2.0	43
150	Differentiated Thyroid Carcinoma in Childhood: Long Term Follow-Up of 72 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 1088-1094.	1.8	243
151	Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. <i>Cancer</i> , 1985, 55, 794-804.	2.0	544
152	External radiotherapy in thyroid cancers. <i>Cancer</i> , 1985, 55, 2062-2071.	2.0	204
153	External radiotherapy in thyroid cancers. <i>Cancer</i> , 1985, 55, 2062-2071.	2.0	143
154	Relationship between Thyrotropin Stimulation and Radioiodine Uptake in Lung Metastases of Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 57, 148-151.	1.8	36
155	Circulating Thyroglobulin and Thyroid Hormones in Patients with Metastases of Differentiated Thyroid Carcinoma: Relationship to Serum Thyrotropin Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980, 51, 513-519.	1.8	122